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Abstract
Background: Prognostic models for repeated events of the same type are highly useful in predicting when a
patient may have a recurrence of a chronic disease or illness. Whilst methods are currently available for analysing
recurrent event data in prognostic models, to our knowledge, most are not widely known or applied in a medical
setting. As a result, often only the first recurrence is analysed meaning valuable information for multiple recurrences
is discarded. Therefore, the aim of this review is to systemically review models for repeated medical events of the
same type, to determine what modelling techniques are available and how they are applied.
Methods: MEDLINE will be used as the primary method to search sources. Various databases from the Cochrane
Library and EMBASE will also be searched. Trial registries such as Clinicaltrials.gov.uk will be searched, as will
registered trials that are ongoing and not yet published. Abstracts submitted to conferences will also be searched,
and non-English sources will also be considered. Studies to be included in the review will be decided based on
PICO guidelines, where the study population and outcomes correspond to this study’s aims and target population.
The prognostic models used in each study chosen for inclusion in the review will be summarised qualitatively.
Discussion: As recurrent event data is not widely analysed in prognostic models, the results from this systematic
review will identify which methods are available and which are commonly used. It is also unknown if certain
methods which will be identified in the review perform better given certain conditions. Therefore, if included
studies assess predictive performance, the results of this review could also provide evidence to determine if certain
models are better fitting dependant on the event rate of the chronic condition. The results will be used to
determine if model selection varies across disease area. The review will also provide an insight into the
development of any new methods used for analysing recurrent events.
Trial registration: The review has been registered on PROSPERO (CRD42019116031).
Keywords: Prognostic factors, Prognostic models, Recurrence, Chronic condition, Prediction, Validation, Meta-
analysis
Background
A chronic condition is defined as a long-term condition
affecting physical health. Although medication and/or
therapies can be taken to control the condition, there is
no cure for a chronic disease or condition [1]. It is esti-
mated that 17.5 billion adults in the UK live with a
chronic condition such as epilepsy, asthma and cardio-
vascular diseases [2]. Many people who live with a
chronic disease or condition are at risk of multiple
recurrences throughout their life time. Being able to pre-
dict when this recurrence may occur would be highly
beneficial to clinicians and patients in terms of treat-
ment choice and patient counselling.
A prognostic factor is a factor which is used to predict
the risk of a recurrence of a chronic disease or condi-
tion, or the chance of recovery [3]. Multiple prognostic
factors can be combined in prognostic models. These
predict outcome for patients, calculating the probability
the patient has of developing a disease or recurrence in
the future [4]. The results can be utilised to determine
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patients who are at a high risk of a recurrence and thus
determine if a patient requires alternative or additional
treatment or intervention. Likewise, the results from the
models can also be used to identify patients who are at
low risk of a recurrence and therefore may require less
frequent follow-up. Currently, prognostic models for re-
current event data are not widely utilised or developed
in research, and commonly only the time until the first
event or recurrence is analysed [5]. However, as patients
living with chronic conditions have numerous recur-
rences over a lifetime, only being able to predict the time
until the first recurrence is not particularly informative,
and a lot of key clinical information is lost. Performing a
systematic review of prognostic models for recurrent
data will identify and summarise models available and
applied in research.
Prognostic factors can be useful in identifying groups
of patients who are at highest risk of recurrence but
can also be combined in prognostic models to predict
individual level of risk of a chronic condition or disease
at a certain timepoint assuming baseline covariates.
Therefore, the results of our systematic review will
evaluate existing methodology and determine whether
the identified methods differ dependant on the event
rate of the chronic condition. This information can
then be utilised to provide evidence for future use of
such methods, informing researchers which method-




The aim of this systematic review is to identify methods
used in prognostic modelling of recurrent event data.
This will be achieved by summarising qualitatively
which models were used and how they were applied. If
data is found to be available, model performance and
predictive capability of disease recurrence and other
outcomes of each of the prognostic models applied will
also be summarised.
Study design
Studies which use and/or develop prognostic models for
recurrent event data to predict the risk of a recurrence
will be assessed for inclusion in the review. No limit will
be placed on the specific type of study design, as rando-
mised controlled trials, cohort studies and case control
studies will all be assessed for inclusion in the review.
Study population
The study population will not be defined by a certain
age group or ethnicity. However, the study population
must include patients who are at risk of experiencing re-
current events in chronic conditions.
Study outcomes
Studies with any outcome regarding recurrent events
will be included, specifically recurrence of symptoms
which typify a chronic condition such as seizures in epi-
lepsy or attacks in asthma.
Setting
No country-specific databases will be searched, as there
is no set study population geographically. However, the
country which the database represents will be considered
when evaluating studies, as will whether the study was
conducted in higher-, lower- or middle-income coun-
tries. This is to account for potential differences in event
rates due to possible varying standards of care across
countries. Access which the studied population may
have to treatment may also be an important factor re-
garding event rate, as those in lower income countries
may not have treatment or therapy widely available to
them and therefore have a higher event rate.
Study selection
This is a methodological review and the specific disease
area will not be specified when deciding which articles
will be included, providing the study is evaluating a
chronic condition or disease where the risk of recur-
rence is the primary area of interest. Studies will be
compared against a developed eligibility checklist to de-
termine if they will be included in the systematic review.
A standardised search filter will be used when searching
studies as part of the literature review—more details of
this can be found below in the “Search approach” sec-
tion—and any full texts which are referenced in papers
will also be evaluated. Key authors of papers will be con-
tacted for further information if necessary [6].
Primary and secondary outcomes
The primary outcome of this systematic review is to
identify methods used within prognostic modelling for
recurrent event data. A secondary outcome, if reported
upon in included studies, is to summarise model per-
formance in terms of how accurate the model predicts
recurrence of a chronic condition or disease. Examples
of these performance measures include discriminatory
statistics such as the C-Statistic or Brier score and cali-
bration statistics such as the calibration slope. Secondary
outcomes will also evaluate the predictive capability of
the prognostic models used to predict not just the recur-
rence but other relevant outcomes. These results will
not only inform future researchers what models there
are available for analysing recurrent event data in prog-
nostic models but will also provide evidence regarding
what model may be better suited to their data.
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Search approach
Bibliographic databases will be searched for studies to
include in the review, with the primary source of inter-
est being the Medical Literature Analysis and Retrieval
System Online (MEDLINE). The Cochrane Library
(Wiley) which will include the Cochrane Database of
Systematic Reviews (CDSR), Health Technology Assess-
ment (HTA) Databases, and Database of Abstracts of
Review of Effects (DARE) as well as Cochrane Con-
trolled Register of Trials (CENTRAL) will also be
searched to identify any potentially similar systematic
reviews from which further appropriate sources can be
identified from. The Excerpta Medica Database
(EMBASE) will also be searched. Searches will be per-
formed using index terms and phrases related to recur-
rent events and prognostic factors. The full search
strategy can be seen in the Appendix.
Public trial registers will also be searched such as Clin-
icaltrials.gov for registered trials in the UK as will the
World Health Organization (WHO) International Clin-
ical Trial Registry to search trials outside of the UK.
Other trial registries will include, but are not limited to,
UK Clinical Research Network Study Portfolio Database
(UKCRN) and metaRegister of Controlled Trials
(mRCT). This will also enable ongoing trials that are not
yet published to be searched [7].
References cited in identified sources will be exam-
ined, and the full papers will be searched to deter-
mine if the full text is available. If necessary, the key
authors of the paper will be contacted. Sources of all
languages and time periods will be searched. To iden-
tify other studies which have not been published yet,
abstracts for conferences relevant to our research will
be searched which apply prognostic models for recur-
rent events. Systematic reviews found which are rele-
vant will also be searched for further studies to
include [6]
Study selection
The initial screening procedure will consist of two in-
dependent reviewers (VW and LJB) who will screen ti-
tles and abstracts, removing any which they feel are
not relevant. This will be done using pre-defined
screening criteria. A key part of these criteria will be if
prognostic modelling methods are used for recurrent
event data. Additionally, the endpoint of the study
must be outcomes associated with recurrences of
symptoms which typify a chronic disease or condition,
for example angina attacks in heart disease. Studies
chosen for inclusion may model the number of recur-
rent events or the time between recurrent events; other
studies related to multiple events will also be consid-
ered. Once titles have been screened, the full texts will
be obtained from those selected and reviewed by the
two independent reviewers separately against full eligi-
bility criteria. In the case of non-English reviews being
considered, relevant sections will be translated. Dis-
crepancies between reviewers that cannot be resolved
by discussion will be discussed with a third reviewer
(CTS). The reviewers’ decisions and reasons for exclu-
sion will be recorded using appropriate reference man-
agement software such as EndNote [8]. The review
process will be documented using the Preferred-
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) flow diagram [9].
Data extraction
A detailed data extraction form will be developed
prior to the systematic review being performed. The
data extraction will be checked by a second reviewer
(LJB) by randomly selecting 10% of studies. Discrep-
ancies will be clarified by a third reviewer (CTS). The
Checklist for critical Appraisal and data extraction for
systematic Reviews of prediction Modelling Studies
(CHARMS) will be utilised at this stage. Study char-
acteristics such as sample size, country and year will
be extracted onto this form, as will study design char-
acteristics which will include the medical condition
under consideration, the design of the study and
length of follow-up. The event rate will also be re-
corded, for example how many events were observed
within the study period and the annual event rate if
possible. Whether the design of the study has any risk
of bias will also be recorded. Primary and secondary
outcomes of the study will be recorded, for example
recurrence of disease along with the disease area or
chronic condition being investigated.
Prognostic factors included in the model will be re-
corded and how they were measured and incorporated
into the model. Whether the prognostic factors in the
model were continuous, categorical, binary or count
data and whether continuous variables have been
dichotomised with a description of how they were de-
rived where possible will be recorded. At which point
in time when a patient is defined as being at risk again
after the first or previous recurrence will be extracted,
allowing for the time measurement of the prognostic
factors to be captured. The prognostic model used in
the final analysis and justifications for how the model
was chosen for analysis will be recorded. Any reported
strengths and weaknesses of the applied method will be
extracted, and if multiple methods are applied in the
same study which method was concluded to be the best
performing with justifications will also be extracted if
provided. Similarly, details regarding how the model
was applied will be extracted. How the model expresses
individual outcome risk will also be extracted such as
the hazard ratio (HR) or incidence rate ratios (IRR)
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along with the associated confidence intervals, which
will also allow for the magnitude of the effect and de-
gree of uncertainty to be summarised. If it is found that
studies apply multiple recurrent event methods to the
same dataset and report multiple results, extracting
measures regarding the magnitude of the effect size and
degree of uncertainty will allow us to determine if a
certain method over- or underestimated the effect
when compared to others or had a higher degree of un-
certainty for example. When pooling the results to-
gether, narratively, it could be that this was a common
occurrence for a method identified.
Whether the study analysed the first recurrence in
standard Cox regression for example as a comparator
to recurrent event analysis will be extracted, as will
the reported effect estimate and confidence interval.
This will allow for a comparison to the recurrent
event analysis methods by assessing the magnitude
and direction of the reported estimated effect size
and degree of uncertainty.
Any internal or external model validation to assess
model performance will also be described if reported,
such as if any discrimination statistics such as the C-
Statistic or area under the curve (AUC) were used to
assess how well the model distinguishes between those
who had the event to those who never did and, simi-
larly, if any calibration statistics were reported such as
the observed/expected event ratio to assess the level of
agreement between the two [7]. This can be used to as-
sess how well the identified methods for recurrent
event analysis perform and could also be used to com-
pare model and predictive performance of other recur-
rent event models.
Assessment of study quality
Publication bias, selection bias and language bias will
all be taken into consideration when reviewing stud-
ies. Risk of bias will be evaluated using guidelines
proposed by Altman [10], and the risk Prediction
model Risk Of Bias ASsessment Tool (PROBAST)
[11] and the QUality in Prognosis Studies (QUIPS)
tool will also be utilised [12].
Study design, sample size, analysis methods and
missing data will be evaluated to determine the qual-
ity and reliability of each study. The reliability of the
prognostic factors and study outcomes used in the
models will be assessed. In terms of sample size,
higher quality studies will be identified as those which
use a pre-specified sample size considering the ex-
pected number of events when the sample size and
power calculation was performed. The sample size
calculation should also allow for multiple comparisons
between factors.
Higher quality studies will be identified as those
which have minimal loss to follow-up in the study
meaning the majority of the data is available for
model validation. Whether internal and external
model validation was performed and whether a clear
description of this is provided will be regarded of a
higher quality than those that do not contain this.
Transparency of the data quality should be evident as
should any missing data and how it was addressed in
the study, for example the use of imputation should
be clearly specified and defined including the number
of imputations used [7].
The quality of the analysis performed will be
assessed based on how prognostic factors were chosen
for the model and how they were measured in the data
capture process. If overfitting of the model and model
optimism was accounted for using bootstrapping and
shrinkage will also be evaluated. Whether the prog-
nostic factors were continuous or if they had been
dichotomised will also be taken into consideration as
dichotomised variables may not be as efficient as con-
tinuous predictors. Although the primary aim is not to
assess the quality of included studies, there is a need
to summarise the quality, as low-quality studies may
not be using the most appropriate statistical method
for example [13]. Similarly, any conclusions drawn
from the included study regarding the results and per-
formance measures of the identified recurrent event
method should be interpreted with caution for lower-
quality studies.
Evidence synthesis
A narrative synthesis will be provided for studies in-
cluded in the review. Appropriate data will be pre-
sented in the form of summary tables and where
relevant graphical representations of the data will be
provided.
Discussion
The results of this systematic review will identify the
statistical models available for prognostic modelling of
recurrent event data and which of these are most com-
monly applied across different clinical areas. Recording
data regarding the predictions from the models such as
the reported risk of a recurrence and degree of uncer-
tainty allows us to determine if certain methods identi-
fied in the review tended to commonly provide biased
estimates compared to others for example. This will be
applicable to studies which apply multiple recurrent
event methods to the same dataset allowing us to com-
pare between them. Extracting any performance mea-
sures which may be reported will also provide insight
into the predictive capability of the methods identified.
The reported strengths and weaknesses will be recorded
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as will the event rate of the conditions being modelled.
This will allow us to determine if certain models work
well dependant on their event rate in the observed study
period. A review of how each of these models is applied
will also be provided, to distinguish any similarities or
differences in reporting between the models and across
clinical areas.
Not focussing on a specific disease area or chronic
condition allows us to examine any potential trends or
patterns within clinical areas to determine if a specific
prognostic model tends to be more commonly applied
when modelling certain diseases or chronic conditions,
thus allowing for a comparison across clinical areas to
be made. As a result, models for recurrent event data
which are not widely applied in research will also be
identified, thus identifying gaps for potential future re-
search into the statistical modelling applications.
Therefore, this review will provide evidence of prog-
nostic models available for recurrent event data,
allowing for the optimisation of analysis of recurrent
event data in the future.
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